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Abstract
This chapter is devoted to the advances in the field of nanoparticles-mediated cancer
treatment. A special attention is devoted to the use of magnetite and silver nanopar‐
ticles. The synthesis and properties of Fe3O4 and Ag nanoparticles as contrast or
antitumoral agents as monolith or component of more complex systems such as
polymer matrix composite materials based on: polymers (chitosan, collagen, poly‐
ethylene glycol, polyacrylates, and polymethacrylates, polylactic acid, etc.) and
various antitumoral agents (cytostatics, natural agents and even nanoparticles-
magnetite, silver, or gold) are discussed. Special attention is paid for the benefits and
risks of using silver and magnetite nanoparticles. In both cases, the discussion focuses
on aspects related to diagnosis and treatment of cancer. The influence of size and shape
[1-3] is important from the materials characteristics as well as from the biological
points of view. The role of magnetite is also analyzed from the point of view of its
influence on the delivery of different components of interests (antitumoral compo‐
nents, analgesics/anti-inflammatory agents, etc.). The potentiating effect of the
nanoparticles over the cytostatics and natural components is highlighted.
Keywords: cancer, magnetite, silver nanoparticles, diagnosis and treatment, hyper‐
thermia, drug delivery
1. Introduction
Cancer is a real problem of our century and one of the leading causes of death, accounting for
one of eight deaths occurring worldwide [4, 5]. Based on the actual data, the International
Agency for Research on Cancer (IARC) estimates ~13.1 million deaths associated to cancer by
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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and reproduction in any medium, provided the original work is properly cited.
2030. It is becoming clear for many researchers that the low survival rate is due to the lack of
adequate drug delivery systems and not due to the lack of potent, natural, or synthetic
antitumoral agents. Therefore, there is a real need to develop carriers and delivery systems
which would be able to deliver the chemotherapeutic agents only at the specific target site and
improve the efficiency of treatment and consequently limiting the unwanted systemic side
effects [6]. Cancer is characterized by rapid, uncontrolled cell differentiation. Due to the fast
cell differentiations, the tumor grows fast but the angiogenesis is slower and consequently
nonmatured or formative vasculature is characteristic for these tumoral tissues. This is why
nanoparticles are able to penetrate the cancer tissue through the leaky vasculature, whereas
tight junctions between endothelial cells in healthy tissue do not allow the penetration [7].
Furthermore, cancer tissue lacks a well-formed lymphatic circulation which is responsible for
tissue homeostasis. This leads to enhanced retention of particles in cancer tissue. This phe‐
nomenon in cancer is called enhanced permeation and retention (EPR) effect. The size of the
drug carrier system plays an important role in retention process [8, 9]. Consequently, the use
of nanoparticles could be a great opportunity for the treatment of cancer.
Cancer that begins in bone tissue is rare in adults and increases in importance in young people.
Bone cancer treatment is a real challenge in this century. It affects especially children and young
people/teenagers (10–20 years) – up to 4-7% of all cancers – and rarely appears in old people
(less than 0.2% of all cancers) [10-12]. Malignant primary bone tumors are usually associated
with an aggressive growth [12]. One of the most common forms of primary bone cancer is
osteosarcoma (which counts for ~35.1% of primary bone cancer). In many cases, bone cancer
treatment involves surgery, radio- and chemotherapy, even if many unconventional therapies
are available; some of the most studied being hyperthermia and photothermia as well as the
use of different nanoparticles due too their intrinsic antitumoral activity. Some of our previous
works proved the possibility of combining surgery with hyperthermia [13], surgery with
chemotherapy [14, 15], as well as surgery with hyperthermia and with antitumoral nanopar‐
ticles [16]. The use of these nanoparticles is beneficial because it can lead to a decrease in the
amount of cytostatics and consequently lower systemic toxicity due to the use of cytostatics.
Beside the treatment, special attention is paid to pain management. In all phases of cancer, the
management of pain is present, the analgesics used being gradually changed from mild
analgesics to even opioids, especially in the advanced forms of cancer when the treatment is
shifted from cure to palliation [17].
Bone cancer treatment involves a different approach compared to other types of cancer
especially due to the particularities of the bony tissue. The most important characteristic of the
bone tissue, which affects bone cancer treatment, is the low diffusivity of the antitumoral
agents inside the tumoral tissue as well as the low penetration ability of different radiations
into the bony tissue [18].
Over the past decades, developments in polymer as well as in nanoparticles chemistry have
allowed synthesis and conjugation of functionalities which can respond to stimuli. This is an
important advance in the field of cancer treatment because it allows not only a passive targeting
strategy but also an active targeting strategy by using carrier–monoclonal antibody conjugates
and carrier–ligand conjugates, which can be activated at desired moment/site. The stimuli-
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responsive polymers can be used in order to design various carrier systems such as micelles,
vesicles, liposomes, gels, micro- and nanospheres, micro- and nanoparticles, and core–shell
structures [5, 19].
Nanoscience and nanotechnologies are of high interest for researchers from all fields of science
allowing exciting opportunities from industry to (nano)medicine, but also unsuspected
menace. In most fields, the researches in the field of nanomaterials and nanotechnologies are
of increasing importance, the most scientific database revealing increasing number of publi‐
cations (papers, reviews or even patents) [20, 21], especially increasing market share of the
nanotechnology products of thousands of billion Euros [22]. A rational use of the nanotech‐
nologies/nanomaterials must be laid down in order to optimize the opportunities/risks ratio.
In the case of cancer and other deadly diseases, higher risks can be assumed in their treatment.
It is well known that there are a lot of “smart polymers” which are stimuli-responsive
polymers. They can be “activated” by pH, temperature, light, electric field or even by dual
stimuli like pH and ionic strength, pH and redox, pH and temperature, etc. [5, 23], as presented
in Scheme 1.
 
Temperature-responsive polymers: 
 Poly(N-isopropylacrylamide); 
 Poly(N-vinylcaprolactam); 
 Polylactic acid 
pH-responsive polymers: 
 Poly(acrylic acid); 
 Poly(methacrylic acid); 
 Poly(lactic-co-glycolic)–polyethylene glycol 
 Poly(acetoacetoxyethyl methacrylate); 
 Poly[2-(diisopropylamino)ethyl methacrylate]; 
 Poly(hexyl methacrylate); 
 Poly[2-(dimethylamine)ethyl methacrylate) 
 poly(methacrylic acid–co-acrylic acid)-co-
polyvinyl-pyrrolidone; 
 2-(N,N-diethylamino)ethyl methacrylate; 
Light-responsive polymers: 
 Poly(N,N-dimethylacrylamide-co-4-phenyl-azophenyl acrylate); 
 Poly(N,N-dimethyl acrylamide-co-4-phenyl-azophenyl acrylamide); 
Electric field-responsive polymers: 
 Poly(dimethylsiloxane); 
 Poly[2-(methacryloyloxy)ethyl phosphorylcholine]; 
 Poly(ethylenediamine-co-1,10-bis(chloro-carbonyl)decane); 
Dual-responsive polymers: 
 Poly(acrylic acid-graft-vinylidenefluoride) – pH and ionic strength. 
Sheme 1. Classes of stimuli-responsive polymers and some of their major representative polymers
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However, in most cases, the delivery mechanism is very complex; the contribution of several
mechanisms has to be considered. The influence of the temperature, for instance, is important.
For instance, even for the non-thermo-sensitive systems the temperature plays an important
role, the delivery being influenced. Usually, the temperature can influence the solubility of the
drug (usually increasing temperature leads to increased solubility) as well as the mobility/
diffusion of the drug (usually these properties increase with the temperature). Similarly, the
pH can influence the solubility of the drugs and consequently influence the delivery rate of
the active components.
2. Role of magnetite in cancer treatment
Magnetite is widely used in the medical field, being recommended due its native magnetic
properties – magnetically guiding possibility, hyperthermia generating property, high loading
capacity of many biological active agents, etc. Magnetic systems offer attractive diagnostic and
treatment possibilities and consequently there are increasingly studied for a lot of biomedical
applications. Superparamagnetic iron oxide nanoparticles (the so-called SPIONs) are usually
used for inducing magnetic-field-responsive functionality of drug delivery systems. For this
purpose, magnetite and/or maghemite can be further coated with a proper hydrophilic shell.
The presence of the shell can dramatically change the properties of the magnetite, making it
suitable for a wide range of medical and nonmedical applications. The main applications of
magnetite and magnetite-based materials are presented in Scheme 2.
 
Applications of magnetite and magnetite-based materials 
 
Biomedical applications 
 Magnetic resonance imaging (MRI) [24-26] 
 Biosensor and bioseparation, including 
DNA separation and isolation [26, 27] 
 Magnetic manipulation of biomolecules 
[25] 
 Drug and gene delivery [28] 
 Drug transport [11, 29] 
 Cancer therapy by hyperthermia [26] 
magnetocytolysis  
 Tissue engineering [26] 
Nonmedical applications 
 Permanent magnets 
 Ferrofluids for mechano-electrical 
applications 
 Environmental contaminant (organic 
and inorganic) removal [30, 31]  
 Magnetic sealing [32] 
 Dampening and cooling mechanisms 
in loudspeakers 
 
Scheme 2. Applications of magnetite 
Sheme 2. Applications of magnetite
2.1. Magnetic materials as contrast agents
Iron oxide nanoparticles have been extensively studied as contrast agents for cancer detection
and monitoring by MRI. They generally produce enhanced proton relaxation rates at signifi‐
cantly lower doses than paramagnetic ions (Gd3+, for instance) because of their larger magnetic
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moment, and they provide negative (dark) contrast by enhancing T2 relaxivity of water
protons.
(Ultrasmall) Super Paramagnetic Iron Oxides are often used for magnetic resonance imaging
– MRI. They consist of iron oxide cores, covered by different hydrophilic macromolecules, for
example, dextran. Their synthesis is generally realized in one step alkaline precipitation
starting from Fe2+ and Fe3+ aqueous precursors. The shell has three main roles: limit the
magnetic core growth during the synthesis, limit the agglomeration due to the sterical
repulsion due to the charged nature of the shell, and reduce the in vivo opsonization process.
In fact, usually these core–shell structures consist of several magnetic cores, more or less
aggregated, embedded into a hydrophilic macromolecules, which are sometimes cross-linked
in a second step for enhancing the mechanical entrapment [33, 34].
2.2. Magnetic supports for drug delivery systems
Magnetite is widely used for obtaining drug delivery systems because it is a good sorbent; it
can be functionalized; and can bind by covalent bonds different drugs, but also because it can
be guided in magnetic field into the tumor (tumoral tissue/organ). The magnetically targeted
drug delivery involves the loading of the magnetic nanoparticles with the antitumoral drug
and the implanting of these magnetite-based nanoparticles into or in the proximity of the tumor
or to inject these nanoparticles in the patient body via the circulatory system. Then, the
magnetic nanoparticles are concentrated into the tumor by using adequate magnetic field. In
this case, the delivery will occur mainly into the tumor and, consequently, the systemic toxicity
will be low [35].
The mechanism of delivery can function differently, depending on the internal and external
factors, as schematically represented in Scheme 3. These delivery mechanisms can be generally
considered for any delivery system as also for magnetic drug delivery systems.
pH-triggered delivery is an essential issue in many medical applications because in many
diseases pH changes occur, or once introduced into the body, the delivery must happen at a
certain pH which corresponds to the pH of the desired tissue/organ. As presented in Scheme
1, there are a lot of pH-sensitive polymers.
Core–shell structures are often used as drug delivery systems. In the case of magnetite, the
extensive use of core–shell structures is explained based on the low chemical stability of the
magnetite as well as due to the nonspecific adsorption of plasma proteins and a rapid clearance
of the particles by the immune system. The presence of different shells can lead to a strong
modification of the surface properties of these micro- and nanostructured particles, which
makes these materials suitable for biomedical applications. Both organic and inorganic
coatings are extensively studied [41, 42].
Chitosan-based magnetic materials are often used as drug delivery systems of different drugs,
including cytostatics. The polycationic structure of chitosan is proved to be effective as an
antimicrobial agent as well as carrier and delivery systems. Many chitosan-based magnetic
drug delivery systems for cancer treatment were developed during the time. Chitosan-coated
magnetite for camptothecin release was obtained via typical precipitation/absorption route.
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Delivery mechanism 
Factors affecting the delivery [5, 16, 35-40] 
Osmotic-controlled 
delivery 
The osmotic-controlled delivery is the simplest mechanism of delivery, the drugs being 
delivered due to the different osmotic concentrations between the drug delivery system and 
the surrounding environment. Most of the drug delivery systems involve this mechanism, its 
share in the overall release process being variable.  
Enzymatic-triggered 
delivery 
This mechanism is especially important in the case of covalently bonded drugs. In this case, 
existent enzyme must recognize the support-drug bond and once the bond is broken the drug 
is free and can manifest its specific antitumoral activity. Proteases, hydrolyses, as well as 
other enzymes can be involved in the support-drug bond breaking. In certain conditions, the 
enzyme can be also introduced into the body, since the magnetic materials is accumulated 
into the desired organ/tissue. 
pH-triggered delivery pH-triggered delivery is often essential for medical applications, especially when the targeted 
application is related to the digestive tract, including the treatment of different forms of 
digestive-tube-associated cancers. The pH of the digestive tract is between 1 and 3 (in 
stomach) and over 8–9. In these conditions, the targeted delivery in stomach or intestines can 
be induced by designing drug delivery systems with pH-sensitive polymers. Such systems 
are also used for orally administered cytostatics delivery when protective measures have to 
be taken because of sensitive cytostatics (proteases from stomach could destroy the 
antitumoral agent).  
Temperature-
triggered delivery 
(including magnetic 
control due to the 
produced 
hyperthermia) 
Temperature is an essential factor that influences the delivery of biological active agents, 
including cytostatics. Many formulations were proposed and tested at preclinical and clinical 
levels. In cancer, temperature can be considered as an internal factor because the tumor cells 
are in continuous replication and proliferation and consequently energy release is happen, 
even if the temperature increase is not very high. Also, especially in cancer treatment, the 
temperature can be considered external factor/stimuli because the intentionally produced 
temperature/hyperthermia leads to cancer cells death. In these conditions, the produced 
temperature is not enough for temperature-responsive systems to be developed. However, 
under hyperthermia conditions (an increase of 4–8oC) as well as along with the implantation 
or injection of temperature-sensitive systems (the temperature increase can be upto 20oC), the 
temperature increase is enough to develop temperature-triggered delivery systems.  
Electromagnetic-
triggered delivery 
External electromagnetic field is applied and, due to the produced hyperthermia, the delivery 
rate is increased. Lipid matrices containing dispersed superparamagnetic iron oxide (SPIO) 
or other magnetite-based systems were investigated as magnetic field responsive drug 
delivery systems. Yi et al. [37] showed that lipid matrices based on myristic alcohol, oleic 
acid-coated SPIO particles, and umbelliferone, was able to deliver umbelliferone when 
external magnetic field was applied. The delivery is an indirect process which is due to the 
heating process and not directly due to the applied alternating magnetic field [38, 39]. In the 
case of lipid matrices containing dispersed superparamagnetic iron oxide, once heated the 
delivered heat leads to phase change in the lipid matrix and, along with melting, drug release 
is dramatically increased. 
When composite materials based on magnetite and cytostatics are obtained, the delivery is 
assured by the increasing diffusion induced by the increasing temperature. It was showed 
that once the alternating electromagnetic field was applied, the delivery rate increased [16].  
Dual or poly-sensitive 
delivery  
There are a lot of complex systems able to respond to two or even more factors. Usually, the 
increasing number of components can lead to an increasing number of factors of controlling 
the delivery. Usually, combining polymers from two independent classes allows a dual 
delivery control. The same observation is correct when using magnetic nanoparticles and 
polymers from certain classes. Magnetic control is very important because can assure 
“targeted delivery: as well as can be used to intensify the delivery rate. 
 
Sheme 3. Delivery mechanism of magnetite or magnetite-based drug delivery systems of cytostatic drugs
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Basically, the synthesis consists in magnetite preparation by precipitation followed by chitosan
and camptothecin adsorption from aqueous solution. The thus obtained camptothecin-loaded
magnetic chitosan nanoparticles have spherical shape and a hydrodynamic radius of 65–
280nm and exhibit low cytotoxicity against 7721 liver cancer cells. The in vitro drug release
from these polysaccharide modified magnetic nanoparticles exhibited a steady and sustained
release profile, after 12 h the overall release of camptothecin being ~20% (in 0.001M PBS, pH
= 7.4, temperature or 37oC) [43-46].
Zhang and Misra [47] developed a novel magnetic drug targeting carrier consisting of magnetic
nanoparticles encapsulated in dextran-g-poly(N-isopropylacrylamide-co-N,N-dimethylacry‐
lamide). This nanostructured system was obtained by functionalization of the magnetic
nanoparticles with 3-mercaptopropionic acid hydrazide (HSCH2CH2CONHNH2) via Fe–S
covalent bonds. The anticancer therapeutic drug, doxorubicin, was attached to the surface of
the functionalized magnetic nanoparticles through an acid-labile hydrazone bond, formed by
the reaction of hydrazide group of 3-mercaptopropionic acid hydrazide with the carbonyl
group of doxorubicin (see Scheme 5).
The developed system is pH-sensitive and could be a valuable system for cancer treatment
when considering the normal pH of the blood (pH=7.4) and the pH of the endosomes of some
cancer cells (pH =~5.0–5.5), since the delivery is faster under acidic conditions. This means that
targeted delivery will be obtained in the acidic regions corresponding to the tumor sites.
Furthermore, due to the presence of magnetite, the magnetic system can be concentrated at
the desired tissue/organ and local hyperthermia can be produced. In these conditions,
additional temperature control can be applied; once the temperature increases, the cumulative
doxorubicin release increases by almost 20%, reaching ~90% after 48 h [47]. The thus designed
stimuli-responsive magnetic system has a lower critical solution temperature (LCST) of ~38oC,
which makes it suitable as carrier system in cancer treatments of humans.
Drug delivery system Active component Delivery mechanism
Polyethylene glycol (linker hydrazone)
Doxorubicin
pH-sensitive mechanism of delivery
induced by drug–polymer bond
breaking (polymer/active component is
realized via a third agent called linker)
Poly(amidoamine) dendrimer (linker hydrazone)
Hyaluronic acid (linker hydrazone)
Melanolactone– polycaprolactone (linker hydrazone)
Sheme 4. Schematic representation of the delivery mechanism in pH-sensitive mechanism
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Drug delivery system Active component Delivery mechanism
N-(2-hydroxypropyl) methacrylamide (linker
hydrazone)
Poly(amidoamine) dendrimer (linker cis-aconityl)
Polyacetal (linker acetal)
Pullalan (amide linker
Poly(aspartate hydrazide) (linker hydrazone) PaclitaxelPolyethylene glycol (linker hydrazone)
Dextran (linker hydrazone) Streptomycin
Alginate (linker cis-aconityl) Daunomycin
Polyethylene glycol and poly(lactic acid)
Paclitaxel
redox-responsive drug delivery
mechanism via disulfuric bond breaking
Polyethylene glycol and oligocholic acids
Gold nanoparticle-pluronic
Poly(ε-caprolactone) and poly(ethyl ethylene
phosphate)
Doxorubicin
Poly(ε -caprolactone), poly(2,4-dinitrophenylthioethyl
ethylene phosphate), and polyethylene glycol
Polyethylene glycol and poly(ε -caprolactone)
Dextran-lipoic acid derivatives
Methoxy polyethylene glycol and poly(ε-caprolactone)
Methacrylic acid and N,N-bis(acryloyl)cystamine
Polyethylene glycol and oligocholic acids Vincristine
Polyethylene glycol, poly(L-lysine), and poly(L-
phenylalanine) Methotrexate
Poly(N-isopropylacrylamide) 5-Fluorouracil
Temperature-triggered delivery
mechanism
Poly(N-vinylcaprolactum)
Pluronic F-127-chitosan CurcuminHydroxypropyl cellulose
Poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide), poly(D,L-lactide-co-glycolide),
poly(ε -caprolactone)
Doxorubicn
Poly(N-isopropylacrylamide-co-acrylamide)-b-
poly(D,L-lactide) Docetaxel
Poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide)-bpoly(D,L-lactide-co-glycolide) Paclitaxel
Poly(N-isopropylacrylamide-co-
N,Ndimethylacrylamide- co-10-undecenoic acid)
nanoparticles
Doxorubicin Complex, dual pH/ temperature-
responsive drug delivery mechanismPoly(N-isopropylacrylamide-co-acrylic acid)-b-
polycaprolactone nanoparticles Paclitaxel
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Drug delivery system Active component Delivery mechanism
Methoxy polyethylene glycol-b-P(N-(2-hydroxypropyl)
methacrylamide dilactate)-co-(N-(2-hydroxypropyl)
methacrylamide-co-histidine, methoxy polyethylene
glycol-b-poly(lactic acid)
Doxorubicin
Poly(D,L-lactide)-g-poly(N-isopropylacrylamide-
comethacrylic acid) nanoparticles 5-Flourouracil
Methacrylic acid and N,N-bis(acryloyl)cystamine
nanogels Doxorubicin
Complex, dual pH/redox responsive
drug delivery mechanism
Polyethylene glycol-SS-poly(2,4,6-
trimethoxybenzylidene-pentaerythritol carbonate)
micelle
Doxorubicin
Methoxy polyethylene glycol-2-mercaptoethylamine-
grafted-poly(L-aspartic acid)-2-(diisopropylamino)
ethylamine-graftedpoly(L-aspartic acid) micelles
Doxorubicin
Polyethylene glycol- Fe3O4 nanoparticles Doxorubicin
Complex, dual pH/ magnetic-
responsive drug delivery mechanism
Methoxy polyethylene glycol-b-poly(methacrylic acid)-
b-poly(glycerol monomethacrylate) coated Fe3O4
nanoparticles
Adriamycin
Methoxy polyethylene glycol-b-(N,N-
dimethylamino)ethyl methacrylate-b-polyglycidyl
methacrylate coated Fe3O4 nanoparticles
Chlorambucil and
Indomethacin
Polyethylene glycol-poly(imidazole L-aspartamide)-2-
vinylpyridine coated Fe3O4-SiO2 nanoparticles
Doxorubicin
1,3,5-Triazaadamantane Fe3O4 capped mesoporous silica
nanoparticles Doxorubicin
Pluronic with Fe3O4 nanoparticles
Doxorubicin Complex, dual temperature/ magnetic-responsive drug delivery mechanismPoly(N-isopropylacrylamide-acrylamide-allylamine)coated Fe3O4 nanoparticles
DNA-capped MSNs CPT, floxuridine Complex, dual temperature/ enzyme-responsive drug delivery mechanism
Poly(oligo(ethylene glycol) acrylate-co-2-(5,5-
dimethyl-1,3-dioxan-2-yloxy)ethyl acrylate) (P(OEGA-
co-DMDEA)) nanogels containing bis(2-
acryloyloxyethyl) disulfide
Doxorubicin,
Paclitaxel
Complex, ternary temperature/pH/
redox-responsive drug delivery
mechanism
Poly(N-isopropylacrylamide-co-methacrylic acid)
(P(NIPAM-co-MAA)) coated magnetic mesoporous
silica nanoparticles Doxorubicin
Complex, ternary temperature/pH/
magnetic-responsive drug delivery
mechanismPoly(N-isopropylacrylamide)-chitosan magnetic
nanohydrogels
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Drug delivery system Active component Delivery mechanism
Fe(II) loaded poly(methacrylic acid) microcontainers
crosslinked by N,N-methylene-bisacrylamide and N,N-
bis(acryloyl)-cystamine
Daunorubicin Complex, ternary pH/redox/magnetic-responsive drug delivery mechanism
Table 1. Most important delivery mechanism of antitumoral agents and some of their most important representatives
(based on [5, 48])
SCH2CH2CONHNH2
NH-NH2
NH-NH2
H2N-HN
SCH2CH2CONHN=C-Doxorubicin
NH-N=C-Doxorubicin
NH-N=C-Doxorubicin
Doxorubicin-C=N-NH
SCH2CH2CONHN=C-Doxorubicin
NH-N=C-Doxorubicin
NH-N=C-Doxorubicin
Doxorubicin-C=N-NH
Fe3O4
surface modification and
functionalization with NH2NH2
          loading with Doxorubicin
via pH sensitive covalent bond
encapsulation in smart polymer
release of Doxorubicin
via pH and termo-sensitive mechanism
free DOXORUBICIN
Scheme 5. Synthesis and dual-sensitive magnetic drug delivery system
Bhatnagar and Venuganti [5] realized a very complex review based on stimuli responsive drug
delivery systems of over 70 smart delivery systems, classifying them function of the delivery
mechanism and active components. Some of the most representative drug delivery systems
are presented in Table 1. It can be seen that the mechanism of delivery is very important because
it can allow a tighter control of release, which is essential in cancer treatment due to the high
toxicity of the cytostatics.
2.3. Magnetic materials as hyperthermia generator
Hyperthermia is an interesting effect of some materials and appears to be of great importance
in cancer treatment. Since discovered, over 4000 years ago [49], magnetite was tested for the
treatment of different types of cancer from primary (breast, colon, bladder, toque, bone, etc.)
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to metastatic cancer [50-56]. The high attractiveness of these materials is related to the easy
targeted hyperthermia, these nanoparticles being easy to move using an adequate magnetic
field to the desired tissue or organ.
Hyperthermia is a technique of the Ancient Egyptians. Records related to the use of hyper‐
thermia in the treatment of (breast) cancer were reported around 2600 BC and later in 2000 BC
and was rediscovered in the late 19th century [53, 57]. In the treatment of cancer, the high
expectations of the use of hyperthermia can be justified taking into account the following
issues. Cancer cells generally perish above 43oC because the oxygen demand is high while the
oxygen transported via the blood is not sufficient (due to incomplete angiogenesis) whereas
normal cells are less affected even at higher temperatures. In addition, tumors are more easily
heated than the surrounding normal tissues, since the blood vessels and nervous system are
poorly developed in the tumor. In fact, the beneficial heat effect is well known and used for a
long time. Different heating techniques of heating of tumors were attempted, including heating
with hot water, infrared waves, ultrasound, as well as microwaves. In the case of deep-seated
tumors, these techniques are not effective and consequently ferromagnetic microspheres have
to be used to generate hyperthermia [58].
Magnetic composite materials are often obtained by combining the useful properties of
magnetic nanoparticles and different organic or inorganic components, the most used being
polymers: collagen, chitosan, chitin, dextran, as well as inorganic oxides like ZnO, SiO2, TiO2,
and titanates [56, 59].
Ferrimagnetic glass ceramic microspheres as well as magnetite microspheres were produced
by different researchers and were reviewed by Kawashita et al. [58]. Magnetite microspheres
of ~20-30 µm were already prepared by Kawashita et al. [58]. Also, glass-ceramics containing
magnetite in a wolastonite and bioglass matrix was proved to be effective in cancer treatment.
The cancer cells were transplanted in rabbit tibiae by inserting into the medullary canal as a
glass ceramic pin. The hyperthermia is generated by placing it into an alternating magnetic
field. Based on these data, it can be assumed that glass-ceramic microspheres (20-30 µm in
diameter) could be easier applied because the cancer cells might be scattered around and
consequently a larger area must be covered. Comparing magnetite and glass-ceramic micro‐
spheres it can be concluded that magnetite exhibits a higher heat generation capacity (41W/g)
compared with the glass-ceramic-loaded magnetite microspheres (10W/g), which is consistent
with the lower magnetite content. Under these conditions, the maximum coercive force
corresponds to a crystallite size of ~40nm.
Muzquiz-Ramos et al. [55] have obtained biomimetic apatite coatings on magnetite particles
for bone cancer treatment. For this purpose, firstly, they obtained magnetite nanoparticles of
~12nm by coprecipitation and, then, by immersing magnetite nanoparticles into simulated
body fluid – SBF or 1.5 SBF (50% more concentrated SBF than human blood plasma – see
concentrations in Table 2) – for certain period of time they deposited HA coating onto the
magnetite nanoparticles. Hydroxyapatite formation is strongly dependent on the composition
and immersion time in SBF. It was found that, the immersion in SBF does not alter the
superparamagnetic behavior of the magnetite core and consequently it can be used as potential
candidates for the treatment of solid bone tumors.
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Na+ K+ Ca2+ Mg2+ Cl- HCO3 - HPO4 2- SO4 2-
Human blood plasma 142.00 5.00 2.50 1.50 148.80 4.20 1.00 0.50
SBF 213.00 7.50 3.75 2.25 223.20 6.30 1.50 0.75
1.5SBF 142.00 5.00 2.50 1.50 103.00 27.00 1.00 0.50
Table 2. Composition of human blood plasma, SBF, and 1.5SBF
In 2010, Andronescu et al. [13] proposed to slightly change the existent protocol of bone cancer
treatment. In short, the protocol involves the combination of surgery and chemotherapy in the
treatment of bone cancer. Depending on several facts, the chemotherapeutic drugs can precede
and/or follow the surgery (Figure 1). During the surgical resection of the tumoral bony tissue,
the surgeon can introduce into the newly resulted defect(s) multifunctional materials. Two
main roles can be identified and have to be noted. First of all, the material can act as a scaffold
contributing to a faster healing and, secondly, it can assure a supplementary, antitumoral
activity based on the delivered components, interactions with the tumoral cells, or produced
hyperthermia.
[With kind permission from Springer Science+Business Media: J Mater Sci—Mater M., Andronescu E, Ficai M, Voicu
G, Ficai D, Maganu M, Ficai. A Synthesis and characterization of collagen/ hydroxyapatite: magnetite composite mate‐
rial for bone cancer treatment. 21, 2010, 2237–2242 [13]
Figure 1. Bone cancer treatment of osteosarcoma
3. Role of metal nanoparticles in cancer diagnostics and treatment
Metal nanoparticles (silver and gold) are widely used in cell imaging, DNA hybridization
detection, proteins interaction, and photothermal therapy due to their extremely strong
absorption and light scattering in the plasmon resonance [60]. In principle, the high attrac‐
tiveness for using gold and silver nanoparticles in the cancer diagnosis and therapy is due to
the unique optical properties, facile surface chemistry, and appropriate size scale. The tumor
detection and treatment can be further improved by controlling size and shape or by conju‐
gation of these nanoparticles with specific ligands/biomarkers [61]. The selective delivery of
the metal nanoparticles is crucial for in vivo imaging and/or therapy. There are several
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strategies for delivery of these nanoparticles into the tumor: topical application for the skin
tumors; direct injection or intraoperative application for the accessible deep tumors, or
intravascular injection for the inaccessible tumors. In the case of tumors localized in hard
tissues, the low diffusion of the body fluids does not assure the necessary flow through these
tissues and consequently through the tumoral tissue and therefore direct, intraoperative
application is necessary.
PEGylated gold or silver nanoparticles can also act as carrier of anticancer chemotherapeutics.
PEG coating assures high biocompatibility, lower agglomeration tendency, and masking
against immune systems. When intravenously injected into the body, it exhibits high retention
time especially in solid tumors. After retention in the tumor, NIR irradiation can be applied
and selective ablation of the nanoparticles-enhanced tumor occurs [62-64]. Molecular specific
imaging and therapy of cancer is easily achieved by the synthetic conjugation of the nanopar‐
ticles with antibodies targeted to receptors overexpressed on the cancer cells.
Silver-based nanostructured materials can be used as bioimaging labels for human lung cancer
H1299 cells as proved by Guo et al.
Xu et al. [65] reported the synthesis of silver and gold spherical metal nanoparticles of various
sizes for IR-sensitive antitumoral activity. Silver nanoparticles (AgNPs) of 10, 20, and 40nm as
well as gold nanoparticles (AuNPs) of 20, 50, and 100nm were prepared and modified with
Fetal Bovine Serum. Also, AgNPs with 12nm diameter were obtained and functionalized with
meso-2,3-dimercaptosuccinic acid and silanes bearing various functional groups including
amino group, short chain PEG and carboxylic group. The thus obtained nanoparticles were
tested on three lines of C6 glioma cells (originated from mouse), U251, and SHG-44 cells
(originated from human GBM). They found that the antitumoral ability of these nanoparticles
is dependent on concentration, IR dose, and nanoparticle size. In short, the smaller nanopar‐
ticles have higher efficiency; the higher irradiation dose leads to higher killing ability; and the
higher concentration leads to lower survival cells. The used capping agent is also important,
even if, the mathematical quantification is more difficult. The tests highlighted that meso-2,3-
dimercaptosuccinic acid and PEGylated silane modified nanoparticles do not affect the cell
sensitivity to radiation but, carboxy- and amino-silane bearing nanoparticles drastically
decrease the cell survival.
Gold nanocages were synthesized by galvanic replacement reaction between Ag template and
HAuCl4. In short, silver nanoparticles of 30–200nm nanocubes are transformed in Au nano‐
boxes and nanocages (nanoboxes with porous walls) with tunable optical properties from blue
(400nm) to near-infrared (1200nm). In order to obtain deeper penetration, near-infrared light
is necessary. At present, three strategies of shifting the surface plasmon resonance from visible
to near-infrared are known:
• form agglomerates from spherical Au nanoparticles;
• by elongating the nanoparticles from spherical gold nanoparticles to nanorods/whiskers;
• by emptying the interiors of spherical nanoparticles to form hollow gold nanostructures.
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Most of these structures can be designed by using adequate capping agents or changing
synthesis route.
4. Silicate-based materials as vectors against tumor cells
Targeted action is many a time necessary for both diagnosis and therapy. Complex systems
based on magnetic core, different shells, and tumoral receptors are of great importance. The
locoregional drug delivery systems are well known to be beneficial because the systemic
toxicity  can  be  reduced compared with  the  other  administration  routes  [4,  10,  14].  The
targeted delivery is very useful especially when local administration is not possible. In most
cancer treatment protocols, active components must be administrated that, due to their high
toxicity, are desired to be delivered at a certain site without spreading to other tissues or
organs. Silicates are interesting materials for industrial  and medical field. Montmorillon‐
ite was largely exploited in biomedical field because it is pH-sensitive and can be loaded
with large amount of drugs into its layered structure. The pH-sensitiveness is determined
by the ability of this material to modify its characteristic interlayer spacing. In acid solutions,
the interlayer spacing is minimal and increases in basic conditions. This property is exploited
in  medicine,  montmorillonite  being  used,  for  instance,  to  deliver  active  components  in
neutral/basic media like colon or intestines. It is also important to mention that montmor‐
illonite-based formulations can be used for oral administration of different active compo‐
nents that are unstable in stomach conditions because of the protective role of the silicate
(proteic drugs, for instance, cannot be administrated orally; the stomach environment will
destroy  them).  For  this  purpose,  montmorillonite  was  tested  for  oral  administration  of
cytostatics  [66-68].  Schematically,  the  targeted  delivery  of  cytostatics  form  silicates  are
presented and discussed in Figure 2.
In oral delivery, the contact of the DDS with the digestive tract is the most important factor
which has to be considered when designing orally administrated DDS. It is important to
mention that the contact of the DDS with gastric acid can destroy the active component(s).
There are a lot of active components which, under the action of gastric acid, became inactive
(inactivation due to the action of pepsin and/or hydrochloric acid), and amongst these active
components there are also many cytostatics which can be inactivated by gastric acid. In these
conditions, some drugs cannot be orally administrated or different protective measures must
be taken. One of the most common protective way is the entrapping of the drug into organic
or inorganic matrix, which, if correctly selected, can release the drug or its complexes at the
intestine/colon level [66]. At this level, different scenarios are possible: free active component(s)
acts locally fighting against colon cancer or, can be absorbed into the blood and enter the blood
circulatory system. At this moment targeted or nontargeted delivery can occur. In the case of
targeted delivery, the active component/complex is predominantly delivered at the desired
tissue/organs due to the presence of recognizing agents linked on the complex or simply, due
to the intratumoral microenvironment, as we presented in Figure 2.
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5. Conclusions
Metal and metal oxide nanoparticles are of great interest for medical and industrial applica‐
tions. Magnetite is an important metal oxide with many potential applications in nanomedi‐
cine. Hyperthermia, targeted drug delivery system, and carrier and contrast agents are the
most known medical applications with proved applicability in cancer diagnosis and treatment.
The properties of magnetite nanoparticles are dependent on size and shape as well as com‐
position and synthesis route. The bare magnetite is usually not recommended for biomedical
applications because the host body recognizes it as a “foreign body” and consequently core–
shell structures are usually obtained and tested for these applications.
Even if long-term toxicity of the nanoparticles is the subject of controversies, the use of gold
and silver nanoparticles bring many advantages compared with other actual alternatives (like
cytostatics). Further studies related to the influence of shape and size, capping agents, receptors
immobilization onto the metal nanoparticles are still necessary. Surface plasmon resonance
can be designed by size and shape and surface functionalization of both silver and gold
nanoparticles. The surface plasmon resonance shift from blue to near-infrared is important
because it allows a better/deeper penetration of the radiation into the body.
Mesoporous silicates are intensively studied for drug delivery and especially for cancer
treatment, alone or in combination with other organic or inorganic polymers. Mesoporous
silicates can be used for targeted delivery systems. These DDSs can be administrated orally,
the delivery being intensified in neutral/basic conditions from intestines/colon.
Figure 2. Schematic representation of cytostatics targeted delivery for oral administration
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